Business
New Strategic Alliance in Spain and Portugal
ProBiotix Health plc has entered into a new exclusive strategic alliance with Bioksan for Spain and Portugal, projected to generate approximately €200,000 annually in ProBiotix sales. This partnership involves Bioksan incorporating ProBiotix's patented LPLDL® probiotic strain into its leading cardiovascular health product, Lipok, replacing red yeast rice due to potential EU prohibitions on Monacolin K. This reformulation addresses a significant market opportunity, as over 40 European supplement brands using Monacolin K, representing an estimated €130 million annual consumer market value, may need to reformulate. The long-term potential for ProBiotix, if all Monacolin K supplements are replaced by their solutions, is estimated at up to €26 million per year. Disclaimer*
About this update from Probiotix Health Plc
26 May 2026 ProBiotix Health plc ("ProBiotix" or the "Company") New Strategic Alliance in Spain and Portugal ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new strategic alliance with Spain based Bioksan. Under the terms of the new exclusive partnership for Spain and Portugal, worth approximately €200,000 a year in ProBiotix sales, ProBiotix has agreed to supply its patented LP LDL ® probiotic strain to Bioksan. As part of a product reformulation, Bioksan will use LP LDL ® as an anchor ingredient to replace red yeast rice which was previously being used w ithin Lipok® a leading cardiovascular health product, positioned within the pharmacy and nutraceutical market in Spain and Portugal. Hitherto Monacolin K, a naturally occurring compound found in red yeast rice, has been used in cardiometabolic supplements to lower cholesterol. Current investigations by the European Food Standards Authority, will potentially lead to Monacolin K being prohibited in the EU in the foreseeable future, due to concerns regarding its pharmacological activity, long-term safety profile and similarities to prescription statin drugs rather than conventional food supplements. If a ban takes place, more than 40 supplement brands in Europe currently using Monacolin K will require reformulation. These products represent an estimated consumer market value of €130 million per annum, creating a significant market opportunity for ProBiotix. A total replacement of all existing monacolin K supplements with YourBiotix turnkey solutions containing LP LDL ® is estimated to offer a long-term potential business opportunity of up €26 million a year. Bioksan is one of the first adopters to reformulate an existing product using LP LDL ® as a replacement for Monacolin K. Several additional projects are currently underway in other EU countries. Founded in 2014, Bioksan is dedicated to the research, development and distribution of innovative next-generation nutraceuticals. The Company collaborates with healthcare professionals to formulate premium, patented and clinically validated ingredients. Bioksan was the first Spanish nutraceutical firm to obtain B Corp certification, and has been recognised by the Financial Times as one of Europe's fastest growing companies. More information can be found at: www.bioksan.com Steen Andersen, CEO of ProBiotix Health, commented: "We are delighted to be working with an early adopter like Bioksan and pleased that they have chosen to include LP LDL ® in their leading cardiovascular health product, Lipok, following a reformulation targeted at cholesterol reduction. We believe there are l imited clinically validated and compliant alternatives for Monacolin K, so expect other European supplement brands to follow suit." Joaquín Solloso, CEO of Bioksan, commented: "This strategic alliance with ProBiotix Health is excellent and reflects our commitment to continuing to build synergies that transform health and global well-being. We are moving steadily toward a healthier, more innovative, and sustainable future." This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement. For further information, please contact: ProBiotix Health plc https://probiotixhealth-ir.com/ [email protected] Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations AlbR Capital Limited Aquis Corporate Adviser and Broker Tel: 020 7469 0930 David Coffman Dan Harris Notes to Editors: ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals. The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
View stock analysis, news, and events for Probiotix Health Plc